Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients
Jiménez, Natalia (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Garcia de Herreros, Marta (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Reig, Oscar (Hospital Clínic i Provincial de Barcelona)
Marín-Aguilera, Mercedes (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Aversa, Caterina (Hospital Clínic i Provincial de Barcelona)
Ferrer-Mileo, Laura (Hospital Clínic i Provincial de Barcelona)
García-Esteve, Samuel (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Rodríguez-Carunchio, Leonardo (Hospital Clínic i Provincial de Barcelona)
Trias, Isabel (Hospital Clínic i Provincial de Barcelona)
Font, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Rodriguez-Vida, Alejo (Institut Hospital del Mar d'Investigacions Mèdiques)
Climent, Miguel Ángel (Instituto Valenciano de Oncología (IVO))
Cros Costa, Sara (Hospital General de Granollers)
Chirivella, Isabel (Hospital Clínic Universitari (València))
Domènech, Montserrat (Althaia Xarxa Assistencial Universitària (Manresa, Catalunya))
Figols, Mariona (Althaia Xarxa Assistencial Universitària (Manresa, Catalunya))
Carles, Joan (Vall d'Hebron Institut d'Oncologia)
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia)
Herrero Rivera, Daniel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Gonzalez-Billalabeitia, Enrique (Hospital Universitario 12 de Octubre (Madrid))
Cívico, Claudia (Hospital General Universitario Morales Meseguer (Múrcia))
Sala-González, Núria (Institut Català d'Oncologia)
Ruiz de Porras, Vicenç (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ribal, María J (Hospital Clínic i Provincial de Barcelona)
Prat, Aleix (Hospital Clínic i Provincial de Barcelona)
Mellado, Begoña (Hospital Clínic i Provincial de Barcelona)

Data:	2024
Resum:	BACKGROUND: Androgen deprivation therapy (ADT) with docetaxel (D) and/or antiandrogen receptor therapies (ARTs) are the standard therapies in metastatic hormone-sensitive prostate cancer (mHSPC). Alterations in the tumor suppressor genes (TSGs) RB1, PTEN, and TP53 are associated with an aggressive evolution and treatment resistance in castration-resistant prostate cancer (CRPC). OBJECTIVE: To study the clinical implications of TSG mRNA expression in mHSPC patients. DESIGN, SETTING, AND PARTICIPANTS: This is a multicenter retrospective biomarker study in mHSPC patients. TSGlow status was defined when two or more out of the three TSGs presented low RNA expression by nCounter in formalin-fixed paraffin-embedded samples and TSGwt for the remaining cases. The microarray data from the CHAARTED trial were analyzed as an independent validation cohort. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Molecular data were correlated with CRPC-free survival (CRPC-FS) and overall survival (OS) by the Kaplan-Meier method and multivariate Cox analysis. RESULTS AND LIMITATIONS: A total of 226 patients were included, of whom 218 were eligible: 93 were treated with ADT and 125 with ADT + D; 75. 7% presented de novo stage IV and 67. 9% high-volume disease. TSGlow (19. 2%) was independently correlated with shorter CRPC-FS (hazard ratio [HR] 1. 8, p = 0. 002) and OS (HR 2, p = 0. 002). In the CHAARTED trial, TSGlow was independently correlated with lower CRPC-FS (HR 2. 2, p = 0. 02); no differences in clinical outcomes according to treatment were observed in TSGlow patients, while a significant benefit was observed for ADT + D in the TSGwt group for CRPC-FS (HR 0. 4, p < 0. 001) and OS (HR 0. 4, p = 0. 001). However, no interaction was observed between TSG signature and treatment in either series. Study limitations are the retrospective design, small sample size, and lack of inclusion of patients treated with ADT + ART. CONCLUSIONS: TSGlow expression correlates with adverse outcomes in patients with mHSPC. The investigation of new therapeutic strategies in these patients is warranted. PATIENT SUMMARY: The low RNA expression of tumor suppressor genes in the tumors is correlated with adverse outcomes in patients with metastatic hormone-sensitive prostate cancer.
Ajuts:	Instituto de Salud Carlos III PI18/714 Ministerio de Ciencia e Innovación RD09/0076/00036 Ministerio de Economía y Competitividad PT13/0010/0009
Nota:	Altres ajuts: Janssen-Pharmaceuticals (212082PCR4056); Astellas General Research Grant (71843877); Cancer Institute/ECOG-ACRIN Biostatistics Center (U10CA180820, U10CA180794, UG1CA233180)
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Androgen deprivation therapy ; Biomarkers ; CHAARTED trial ; Docetaxel ; Hormone-sensitive prostate cancer ; Tumor suppressor genes
Publicat a:	European urology oncology, Vol. 7 Núm. 4 (August 2024) , p. 954-964, ISSN 2588-9311

DOI: 10.1016/j.euo.2023.12.012

11 p, 1.9 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats